Nuvectis Pharma (NVCT) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Nuvectis Pharma (NVCT).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | ||||||||||||||||||||
Research And Development | 4.11M (-19.25%) | 5.09M (-11.79%) | 5.77M (+59.83%) | 3.61M (-1.90%) | 3.68M (-18.22%) | 4.50M (+59.57%) | 2.82M (-4.08%) | 2.94M (+10.53%) | 2.66M (-37.56%) | 4.26M (-5.12%) | 4.49M (+5.40%) | 4.26M (+79.75%) | 2.37M (-46.14%) | 4.40M (-2.65%) | 4.52M (+80.08%) | 2.51M (+38.67%) | 1.81M (+58.77%) | 1.14M (-72.60%) | 4.16M | - |
Selling General And Administrative | 2.15M (-15.02%) | 2.53M (+25.25%) | 2.02M (-32.21%) | 2.98M (+57.67%) | 1.89M (-3.08%) | 1.95M (+26.62%) | 1.54M (-9.41%) | 1.70M (-2.30%) | 1.74M (-33.08%) | 2.60M (+55.69%) | 1.67M (+10.60%) | 1.51M (-12.72%) | 1.73M (-27.31%) | 2.38M (+67.61%) | 1.42M (+32.71%) | 1.07M (-6.14%) | 1.14M (+1.79%) | 1.12M (+119.61%) | 510K (+2450.00%) | 20K |
Operating Expenses | 6.26M (-17.85%) | 7.62M (-2.18%) | 7.79M (+18.03%) | 6.60M (+18.49%) | 5.57M (-13.64%) | 6.45M (+47.94%) | 4.36M (-6.03%) | 4.64M (+5.45%) | 4.40M (-35.95%) | 6.87M (+11.53%) | 6.16M (+6.76%) | 5.77M (+40.73%) | 4.10M (-39.53%) | 6.78M (+14.14%) | 5.94M (+66.39%) | 3.57M (+21.02%) | 2.95M (+29.96%) | 2.27M (-51.39%) | 4.67M (+23250.00%) | 20K |
Operating Income | ||||||||||||||||||||
Operating Income | -6.26M (-17.85%) | -7.62M (-2.18%) | -7.79M (+18.21%) | -6.59M (+18.31%) | -5.57M (-13.64%) | -6.45M (+47.94%) | -4.36M (-6.03%) | -4.64M (+5.45%) | -4.40M (-35.95%) | -6.87M (+11.53%) | -6.16M (+6.76%) | -5.77M (+40.73%) | -4.10M (-39.53%) | -6.78M (+14.14%) | -5.94M (+66.39%) | -3.57M (+21.43%) | -2.94M (+30.09%) | -2.26M (-51.61%) | -4.67M (+23250.00%) | -20.00K |
Ebit | -6.26M (-17.85%) | -7.62M (-2.18%) | -7.79M (+18.21%) | -6.59M (+18.31%) | -5.57M (-13.64%) | -6.45M (+47.94%) | -4.36M (-6.03%) | -4.64M (+5.45%) | -4.40M (-35.95%) | -6.87M (+11.53%) | -6.16M (+6.76%) | -5.77M (+40.73%) | -4.10M (-39.53%) | -6.78M (+14.14%) | -5.94M (+66.39%) | -3.57M (+21.43%) | -2.94M (+30.09%) | -2.26M (-51.61%) | -4.67M (+23250.00%) | -20.00K |
EBITDA | -6.05M (-17.24%) | -7.31M (-2.01%) | -7.46M (+17.85%) | -6.33M (+18.76%) | -5.33M (-14.72%) | -6.25M (+50.60%) | -4.15M (-6.32%) | -4.43M (+6.24%) | -4.17M (-37.01%) | -6.62M (+12.59%) | -5.88M (+2.98%) | -5.71M (+40.99%) | -4.05M (-39.55%) | -6.70M (+13.95%) | -5.88M (+64.71%) | -3.57M (+21.43%) | -2.94M (+30.09%) | -2.26M (-51.61%) | -4.67M (+23250.00%) | -20.00K |
Net Income | ||||||||||||||||||||
Net Income From Continuing Operations | -6.05M (-17.24%) | -7.31M (-2.01%) | -7.46M (+17.85%) | -6.33M (+18.76%) | -5.33M (-14.72%) | -6.25M (+50.60%) | -4.15M (-6.32%) | -4.43M (+6.24%) | -4.17M (-37.01%) | -6.62M (+12.59%) | -5.88M (+2.98%) | -5.71M (+40.99%) | -4.05M (-39.55%) | -6.70M (+13.95%) | -5.88M (+64.71%) | -3.57M (+21.43%) | -2.94M (+30.09%) | -2.26M (-51.61%) | -4.67M (+23250.00%) | -20.00K |
Net Income | -6.05M (-17.24%) | -7.31M (-2.01%) | -7.46M (+17.85%) | -6.33M (+18.76%) | -5.33M (-14.72%) | -6.25M (+50.60%) | -4.15M (-6.32%) | -4.43M (+6.24%) | -4.17M (-37.01%) | -6.62M (+12.59%) | -5.88M (+2.98%) | -5.71M (+40.99%) | -4.05M (-39.55%) | -6.70M (+13.95%) | -5.88M (+64.71%) | -3.57M (+21.43%) | -2.94M (+30.09%) | -2.26M (-51.61%) | -4.67M (+23250.00%) | -20.00K |